Introduction to Pharmacoeconomics
-
Conferences
-
Upcoming Conferences
- ISPOR 2019
- ISPOR Latin America Summit 2019
- ISPOR Latin America 2019
- ISPOR Europe 2019
-
ISPOR Summit 2019
- Past Conferences
- Register
- Submit Abstract
- Exhibits & Sponsorships
- Awards & Grants
-
Upcoming Conferences
-
Education & Training
- In-Person Training
-
Virtual Training
-
Distance Learning
- Introduction to Outcomes Research
- Introduction to Systematic Reviews & Meta-Analysis
- Systematic Review & Meta-Analysis: Applications
- Introduction to Pharmacoeconomics
- Cost-of-Illness/Cost-Estimation (COI/CE)
- Cost-Minimization/Cost-Consequence (CMA/CCA)
- Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis (CUA)
- Modeling Health Care Costs – Part I: Characteristics of Health Care Costs
- Modeling Health Care Costs – Part II: Methods and Guidelines for Estimating Health Care Costs
- Modeling Health Care Costs – Part III: Estimation from Censored Data
- Introduction to Budget Impact Analysis (BIA) - Part I
- Introduction to Budget Impact Analysis (BIA) - Part II
- Markov Model Toolkit: Concepts, Assumptions and Examples
- An Introduction to Choice-Based Conjoint Analysis (Discrete Choice Experiments)
- Health-Related Quality of Life (HRQOL) – Basics
- Patient Reported Outcomes: Analysis and Interpretation
- Patient Reported Outcomes: Instrument Development
- Item Response Theory: A Conceptual Introduction
- Preparing for Multinational Clinical Trials: Translation and Cultural Adaptations of PRO Measures
- Evidence Generation for Patient Reported Outcome (PRO) Label Claims (FDA Requirements)
- Intermediate Retrospective Observational Study - Propensity Scoring Methods
- Use of Public Survey Data in Health Outcomes Research
-
Webinars
- Using RWE to Improve Healthcare Decision-making in Asia Pacific
- Top 10 HEOR Trends of 2019
- The Use of MCDA for HTA Agencies
- MCDA - How to Guide of Different Methods for Assessment of Rare Disease HT
- Virtualizing Long-Term Follow-Up Studies for Gene Therapy Products
- Is the FDA's New Guidance a Watershed Moment for Real-world Evidence?
-
Distance Learning
-
Calendar
Faculty
Course Description
This module is an introduction to the role of pharmacoeconomics (PE) in medical decision making from multiple perspectives. It will introduce the concepts of types of PE/Cost-effectiveness analysis (CEA), general computation involved in these analyses, and how to evaluate a CEA.
Learning Objectives
By the end of the Introduction to Pharmacoeconomics (PE) module, you will be able to:
- State the role of PE in medical decision making.
- Define the types of PE/cost-effectiveness analyses (CEA).
- Explain the societal, patient and payer tradeoffs involved in using PE for medical decision making.
- Understand the difference between and usefulness of average and incremental (marginal) CEA.
- State the definition of utility measurement and its use in cost-utility analysis.
- Understand the elements essential to a published CEA.